Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10108	Companies
207142	Keywords
137283	Articles
109792	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 01/07/2026 at 07:00, 2 months 21 days ago

Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai

Schizophrenia Newron Pharmaceuticals Evenamide Phase III EA Pharma
BRIEF

published on 01/06/2026 at 07:05, 2 months 22 days ago

Newron Pharmaceuticals renforce son portefeuille de propriété intellectuelle pour Evenamide

Schizophrénie Brevet Newron Pharmaceuticals Evenamide Modulation Du Glutamate
BRIEF

published on 01/06/2026 at 07:05, 2 months 22 days ago

Newron Pharmaceuticals Strengthens IP Portfolio for Evenamide

Patent Schizophrenia Newron Pharmaceuticals Evenamide Glutamate Modulation
PRESS RELEASE

published on 01/06/2026 at 07:00, 2 months 22 days ago

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Newron Pharmaceuticals obtains new EU Composition of Matter Patent EP4615820 for Evenamide, extending exclusivity into 2044

Patent Intellectual Property Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 12/08/2025 at 07:05, 3 months 20 days ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
BRIEF

published on 12/08/2025 at 07:05, 3 months 20 days ago

Newron lance une étude de phase III aux États-Unis sur l'événamide pour la schizophrénie

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Étude De Phase III
PRESS RELEASE

published on 12/08/2025 at 07:00, 3 months 20 days ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2
BRIEF

published on 10/02/2025 at 07:05, 5 months 26 days ago

Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
BRIEF

published on 10/02/2025 at 07:05, 5 months 26 days ago

Newron Pharmaceuticals présente l'Evenamide au congrès ECNP 2025

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Congrès De L'ECNP
PRESS RELEASE

published on 10/02/2025 at 07:00, 5 months 26 days ago

Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress

Accesswire

Published on 03/28/2026 at 01:00, 7 hours 31 minutes ago

Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 7 hours 36 minutes ago

Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 00:50, 7 hours 41 minutes ago

"Rise" Selected as NASA Artemis II Moon Mascot
Published on 03/27/2026 at 22:45, 9 hours 46 minutes ago

Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:30, 10 hours 1 minute ago

Usha Resources Completes Extended Induced Polarization Survey at the Southern Arm Property

View all ACCESSWIRE

EQS Group

Published on 03/28/2026 at 01:42, 6 hours 49 minutes ago

EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 10 hours 33 minutes ago

Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 21:58, 10 hours 33 minutes ago

Kaufman & Broad SA: Mise à disposition du Document d'Enregistrement Universel 2025
Published on 03/27/2026 at 20:08, 12 hours 23 minutes ago

EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria
Published on 03/27/2026 at 19:30, 13 hours 1 minute ago

Turning Potential into Reality: Future 500 Ignites Scale-Up Momentum in Europe

Les Echos

Published on 03/28/2026 at 07:00, 1 hour 31 minutes ago

Groupe DLSI - Résultat 2025
Published on 03/27/2026 at 19:06, 13 hours 25 minutes ago

Mersen : Déclaration des transactions sur actions propres
Published on 03/27/2026 at 19:06, 13 hours 25 minutes ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 13 hours 39 minutes ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:52, 13 hours 39 minutes ago

Crédit Agricole CIB annonce la publication de son Document d’enregistrement universel 2025

View all LES ECHOS COMFI WIRE